VINC
Closed
Vincerx Pharma Inc
0.714
0.000 (0.00%)
Last Update: 06 Sep 2024 23:00:00
Yesterday: 0.714
Day's Range: 0.6901 - 0.7898
Send
sign up or login to leave a comment!
When Written:
0.937
Vincerx Pharma Inc. is a clinical-stage biopharmaceutical company that focuses on developing targeted small molecule drugs for the treatment of cancer. The company was founded in 2018 and is headquartered in San Diego, California.
Vincerx's pipeline includes multiple drug candidates that target specific genetic mutations and signaling pathways associated with cancer. These candidates include inhibitors of the Wnt signaling pathway, which is implicated in the development of various cancers, and inhibitors of the KRAS oncogene, which is mutated in many types of cancer.
The company's lead drug candidate, VTX-27, is a small molecule inhibitor of the Wnt signaling pathway that is being developed for the treatment of solid tumors. VTX-27 is currently in Phase 1 clinical trials.
Vincerx has partnerships with several academic institutions and biopharmaceutical companies to advance its drug development programs. The company also has a strategic collaboration with Bayer AG to develop small molecule inhibitors of the Wnt signaling pathway.
Vincerx went public in August 2020 and trades on the NASDAQ under the ticker symbol "VINC".
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Vincerx's pipeline includes multiple drug candidates that target specific genetic mutations and signaling pathways associated with cancer. These candidates include inhibitors of the Wnt signaling pathway, which is implicated in the development of various cancers, and inhibitors of the KRAS oncogene, which is mutated in many types of cancer.
The company's lead drug candidate, VTX-27, is a small molecule inhibitor of the Wnt signaling pathway that is being developed for the treatment of solid tumors. VTX-27 is currently in Phase 1 clinical trials.
Vincerx has partnerships with several academic institutions and biopharmaceutical companies to advance its drug development programs. The company also has a strategic collaboration with Bayer AG to develop small molecule inhibitors of the Wnt signaling pathway.
Vincerx went public in August 2020 and trades on the NASDAQ under the ticker symbol "VINC".
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!